#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
Click to read this study in Journal of Clinical Oncology.
Read More
Oncology
Imiquimod noninferior to surgery in management of vulvar high-grade squamous intraepithelial lesions
1. Complete clinical response at 6 months was similar in both the topical imiquimod and surgery...
Read More
The antibody drug conjugate MRGOO3 is a promising for use in EGFR-expressing cancers
1. The median progression free survival for all cancer-types was 2.8 months. 2. Most of the...
Read More
Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer
1. A combination of androgen deprivation therapy, docetaxel, and abiraterone (“triplet therapy”)...
Read More
Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer
1. Patients with resectable non-small cell lung cancer (NSCLC) receiving neoadjuvant nivolumab in...
Read More
Treatment with chemoradiotherapy before systemic chemotherapy for rectal adenocarcinoma is a potential non-surgical option
1. Disease-free survival was not impacted by the order in which chemoradiotherapy CRT and systemic...
Read More
#VisualAbstract: Upper neck irradiation is noninferior to whole neck irradiation for newly diagnosed nasopharyngeal carcinoma
Click to read this study in The Lancet Oncology.
Read More
Support for Liver Cancer at ASCO 2022
Liver cancer is the third-highest cause of cancer-related deaths worldwide, and incidence of...
Read More
Increases in muscle-strengthening activities may reduce mortality risk and certain diseases
1. Muscle-strengthening activities (MSA) were associated with a lower risk of cardiovascular...
Read More
#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in premenopausal women with ER+ breast cancer and ovarian suppression
Click to read this study in The Lancet Oncology.
Read More
Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer
1. Patients who underwent segmentectomy reported a significantly greater 5-year overall survival...
Read More
Lenvatinib plus pembrolizumab show similar health-related quality-of-life outcomes in patients with advanced renal cell carcinoma compared to sunitinib
1. The median follow-up period for health-related quality-of-life (HRQOL) outcomes analyses was...
Read More
Ivosidenib and azacitidine showed significant clinical benefit in newly diagnosed IDH1-mutated acute myeloid leukemia
1. Event-free survival and median overall survival were significantly longer in the combination...
Read More
COVID-19 pandemic associated with reductions in delivery of cancer care services in Ontario, Canada
1. This population-based cohort study demonstrated that there was a 20.7% reduction in cancer care...
Read More
#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer
1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher...
Read More
#VisualAbstract: Trastuzumab does not improve survival in patients with esophageal adenocarcinoma with HER2 overexpression
Click to read this study in The Lancet Oncology.
Read More
Comparison of mastectomy and breast reconstruction versus conservative surgery with radiation
1. At 10-year follow-up, patients with early-stage breast cancer who underwent mastectomy with...
Read More
Cabozantinib may be a viable first-line treatment in metastatic renal cell collecting duct carcinoma
1. Objective response rate was 35%, with 1 patient showing a complete response and 7 showing a...
Read More
Elevated neutrophil-lymphocyte ratio associated with poor prognosis for head and neck cancer
1. This single-centred, observational cohort study demonstrated that among patients with head and...
Read More
Pembrolizumab did not show overall survival benefit in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer
1. The median overall survival for pembrolizumab versus chemotherapy was not statistically...
Read More